Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204 ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1-2 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1-2, 12.2008
- Creator
-
Molina, JM
- Contributor
-
Cordes, C.
Ive, P.
Vibhagool, A.
Vanveggel, S.
Williams, P.
Boven, K.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P2
- URN
-
urn:nbn:de:1111-2016052057022
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Molina, JM
- Cordes, C.
- Ive, P.
- Vibhagool, A.
- Vanveggel, S.
- Williams, P.
- Boven, K.
- SpringerLink (Online service)
Other Objects (12)
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong – a single center study
Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals
Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients
Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong – a single center study
Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals
Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients
Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong – a single center study
Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals
Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients
Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China